Expert Consensus of the Russian Society of Cardiology, the Society of Heart Failure Specialists, the Russian Association of Oncologists, and the Eurasian Association of Cardio-Oncologists. “Cardioprotection 2025: Modern Approaches to Preventing Cardiovasculatoxicity in Antitumor Therapy”. Part II. Primary Prevention of Cardiovasculatoxicity: a Strategy for Protecting the Myocardium and Vessels

The aim is to present expert-agreed guidelines for the primary prevention of cardiovasculotoxicity of anticancer therapy as part of the Cardioprotection 2025 Consensus of the Russian Society of Cardiology, the Society of Heart Failure Specialists, the Russian Association of Oncologists, and the Eurasian Association of Cardio-Oncologists. The second part of the Consensus focuses on strategies for protecting the myocardium and blood vessels before or at early stages of anticancer treatment. The document addresses the key principles of primary prevention of cardiovasculotoxicity: interdisciplinary collaboration between cardiologists and oncologists at the stage of treatment scheduling, the possibility of managing modifiable risk factors, pharmacological cardioprotection, approaches to preventive screening (including clinical evaluation, biomarkers, and imaging), non-pharmacological prevention (physical activity, nutritional status correction, artificial intelligence, and digital monitoring management), and specific features of prophylaxis in the treatment with key anticancer drug classes (anthracyclines, HER2-targeted agents, tyrosine kinase inhibitors, anti-VEGF agents, immune checkpoint inhibitors). This document aims to optimize patient management to reduce the risk of cardiovascular complications during anticancer therapy.

1. President of Russia. Presidential Address to the Federal Assembly. 2025. [Internet] Available at: http://kremlin.ru/events/president/news/73585

2. Ministry of Health of the Russian Federation. The final 2024 board and plans for 2025. Report by Russian Minister of Health M.A. Murashko. 2025. [Internet] Available at: https://minzdrav.gov.ru/special/news/2025/05/16/25211-itogovaya-kollegiya-2024-i-plany-na-2025-klyuchevaya-zadacha-sistemy-zdravoohraneniya-sohranit-zhizni-i-zdorovie-grazhdan

3. Romann SW, Frey N, Lehmann L. The Cardio-Oncology Guideline - A Comprehensive Approach to Managing Cardiovascular Risks in Cancer Patients. Deutsche Medizinische Wochenschrift. 2024;149(12):719–23. DOI: 10.1055/a-2104-6363

4. Bloom MW, Vo JB, Rodgers JE, Ferrari AM, Nohria A, Deswal A et al. Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America. Journal of Cardiac Failure. 2025;31(2):415–55. DOI: 10.1016/j.cardfail.2024.08.045

5. Rao VU, Deswal A, Lenihan D, Dent S, Lopez-Fernandez T, Lyon AR et al. Quality-of-Care Measures for Cardio-Oncology: An ICOS and ACC Cardio-Oncology Leadership Council Perspective. JACC: CardioOncology. 2025;7(3):191–202. DOI: 10.1016/j.jaccao.2024.11.003

6. Rakisheva A, Farmakis D, Attanasio A, Genis AB, Cohen‐Solal A, Gulati G et al. Prevention of cancer therapy‐related cardiac dysfunction and heart failure in cancer patients and survivors. A Clinical Consensus Statement of the Heart Failure Association, the European Association of Preventive Cardiology of the ESC, and the ESC Council of Cardio‐Oncology. European Journal of Heart Failure. 2025;ejhf.3753. DOI: 10.1002/ejhf.3753

7. Kobalava Zh.D., Konradi A.O., Nedogoda S.V., Shlyakhto E.V., Arutyunov G.P., Baranova E.I. et al. 2024 Clinical practice guidelines for Hypertension in adults. Russian Journal of Cardiology. 2024;29(9):230–329. DOI: 10.15829/1560-4071-2024-6117

8. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). European Heart Journal. 2022;43(41):4229–361. DOI: 10.1093/eurheartj/ehac244

9. Ezhov M.V., Kukharchuk V.V., Sergienko I.V., Alieva A.S., Antsiferov M.B., Ansheles A.A. et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):250–97. DOI: 10.15829/1560-4071-2023-5471

10. Liu R, Fan C, Liu X, Li M, Zhang Y, Zhang M. Evaluating cardioprotective strategies for anthracycline-induced cardiotoxicity in breast cancer: insights from a systematic review and network meta-analysis. CardioOncology. 2025;11(1):65. DOI: 10.1186/s40959-025-00332-7

11. Han K-T, Kim S. Lipid-lowering drug adherence and combination therapy effects on gastrointestinal cancer in patients with dyslipidemia without diabetes: a retrospective cohort study in South Korea. BMC Cancer. 2022;22(1):156. DOI: 10.1186/s12885-022-09250-8

12. Iakobishvili Z, Hasin T, Klempfner R, Shlomo N, Goldenberg I, Brenner R et al. Association of Bezafibrate Treatment With Reduced Risk of Cancer in Patients With Coronary Artery Disease. Mayo Clinic Proceedings. 2019;94(7):1171–9. DOI: 10.1016/j.mayocp.2018.10.026

13. Mohammadi KA, Brackin T, Schwartz GG, Steg PG, Szarek M, Manvelian G et al. Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials. Cancer Medicine. 2023;12(16):16859–68. DOI: 10.1002/cam4.6310

14. Dedov I.I., Shestakova M.V., Sukhareva O.Yu. Standards of Specialized Diabetes Care. Edited by Dedov I. I., Shestakova M.V., Sukhareva O.Yu. 12th Edition. M.; 2025. ALG_CD_20250503_250513_073615.

15. Adams SC, Rivera-Theurel F, Scott JM, Nadler MB, Foulkes S, Leong D et al. Cardio-oncology rehabilitation and exercise: evidence, priorities, and research standards from the ICOS-CORE working group. European Heart Journal. 2025;46(29):2847–65. DOI: 10.1093/eurheartj/ehaf100

16. Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M et al. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. European Journal of Cancer. 2018;94:126–37. DOI: 10.1016/j.ejca.2018.02.005

17. Meattini I, Becherini C, Martella F, Del Bene MR, Saieva C, Bacci C et al. Cardioprotection in patients with anthracycline-treated breast cancer: final analysis from the 2 × 2 randomized, placebo-controlled, double-blind SAFE trial. ESMO Open. 2025;10(6):105116. DOI: 10.1016/j.esmoop.2025.105116

18. Vacharanukrauh P, Miller KJ, Alif SM, Grace F, Rahman MA. Pharmacological interventions for anthracycline-induced cardiotoxicity in breast cancer: a systematic review and meta-analysis of randomized controlled trials. Breast Cancer Research and Treatment. 2025;214(1):1–23. DOI: 10.1007/s10549-025-07791-7

19. Vaduganathan M, Hirji SA, Qamar A, Bajaj N, Gupta A, Zaha VG et al. Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients With Cancer Undergoing Chemotherapy. JACC: CardioOncology. 2019;1(1):54–65. DOI: 10.1016/j.jaccao.2019.08.006

20. He D, Hu J, Li Y, Zeng X. Preventive use of beta-blockers for anthracycline-induced cardiotoxicity: A network meta-analysis. Frontiers in Cardiovascular Medicine. 2022;9:968534. DOI: 10.3389/fcvm.2022.968534

21. Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, de Caralt TM et al. Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant Hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). Journal of the American College of Cardiology. 2013;61(23):2355–62. DOI: 10.1016/j.jacc.2013.02.072

22. Tarantini L, Gallucci G, Inno A, Camerini A, Canale ML, Larocca M et al. A New Era, New Risks: The Cardio-Oncology Perspective on Immunotherapy in Non-Small Cell Lung Cancer. Cancers. 2025;17(21):3443. DOI: 10.3390/cancers17213443

23. Chaulin A. Cardiotoxicity as a Possible Side Effect of Statins. Reviews in Cardiovascular Medicine. 2023;24(1):22. DOI: 10.31083/j.rcm2401022

24. Neilan TG, Quinaglia T, Onoue T, Mahmood SS, Drobni ZD, Gilman HK et al. Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial. JAMA. 2023;330(6):528–36. DOI: 10.1001/jama.2023.11887

25. Bonatto MG, Avila MS, Ayub Ferreira SM, Lechinewski LD, Torres R de A, Costa A de N et al. Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial. Circulation. 2025;Online ahead of print. DOI: 10.1161/CIRCULATIONAHA.125.073322

26. Hsu Y, Lee C, Chung W, Lee W, Lee K, Tsai J et al. Primary cardioprotective effect of sacubitril/valsartan in breast cancer patients receiving adjuvant therapy. European Journal of Heart Failure. 2025;ejhf.3758. DOI: 10.1002/ejhf.3758

27. Omland T, Heck SL, Holte E, Lilleaasen AM, Gynnild MN, Fagerland MW et al. Sacubitril/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. Circulation. 2025;152(16):1136–45. DOI: 10.1161/CIRCULATIONAHA.125.076616

28. Daniele AJ, Gregorietti V, Costa D, López – Fernández T. Use of EMPAgliflozin in the prevention of CARDiotoxicity: the EMPACARD – PILOT trial. Cardio-Oncology. 2024;10(1):58. DOI: 10.1186/s40959-024-00260-y

29. Wu W, Wang Y, Xie J, Fan S. Empagliflozin: a potential anticancer drug. Discover Oncology. 2023;14(1):127. DOI: 10.1007/s12672-023-00719-x

30. Hsieh P-L, Chu P-M, Cheng H-C, Huang Y-T, Chou W-C, Tsai K-L et al. Dapagliflozin Mitigates Doxorubicin-Caused Myocardium Damage by Regulating AKT-Mediated Oxidative Stress, Cardiac Remodeling, and Inflammation. International Journal of Molecular Sciences. 2022;23(17):10146. DOI: 10.3390/ijms231710146

31. Yang H, Huang S, Heng X, Zhang K, Xin W, Sun N et al. Herbacetin mitigates oxidative stress and ferroptosis to protect against doxorubicin-induced cardiotoxicity. Biochemical Pharmacology. 2025;240:117117. DOI: 10.1016/j.bcp.2025.117117

32. Kaplan O, Bozdag Kaplan N. Evaluation of dexrazoxane effect on preventing acute cardiac arrhythmia in patients with breast cancer treated with neoadjuvant/adjuvant anthracycline‐based chemotherapy. International Journal of Clinical Practice. 2021;75(11):e14705. DOI: 10.1111/ijcp.14705

33. Van Aken ESM, Gandhi AK, O’Cathail SM, Borst G, Barriuso J, Fokas E et al. ESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4/6, HER2, PARP, or mTOR inhibitors. Radiotherapy and Oncology. 2025;111330. DOI: 10.1016/j.radonc.2025.111330

34. Kahan J, Martinez C, Tsien C. Critical Appraisal of Proton Therapy for Patients with Central Nervous System (CNS) Malignancies. Current Treatment Options in Oncology. 2023;24(8):988–1003. DOI: 10.1007/s11864-023-01097-w

35. Kelters IR, Printezi MI, Ballesta A, Dierickx P, Koop Y, Innominato PF et al. Chronotherapy as a novel strategy to limit anthracycline-induced cardiotoxicity. Cardiovascular Research. 2025;121(14):2144–56. DOI: 10.1093/cvr/cvaf179

36. Bhasin V, Vakilpour A, Scherrer-Crosbie M. Statins for the Primary Prevention of Anthracycline Cardiotoxicity: A Comprehensive Review. Current Oncology Reports. 2024;26(10):1197–204. DOI: 10.1007/s11912-024-01579-6

37. Felix N, Nogueira PC, Silva IM, Costa TA, Campello CA, Stecca C et al. Cardio-protective effects of statins in patients undergoing anthracycline-based chemotherapy: An updated meta-analysis of randomized controlled trials. European Journal of Internal Medicine. 2024;126:43–8. DOI: 10.1016/j.ejim.2024.04.007

38. Karamat M, Hussain B, Ahmed MM, Hamza M, Mir J, Alamri A et al. Deciphering the cardioprotective effects of statins in anthracyclinerelated cardiac dysfunction: A systematic review and meta-analysis. American Journal of Preventive Cardiology. 2024;20:100874. DOI: 10.1016/j.ajpc.2024.100874

39. Lee J, Tan S, Ramkumar S. Challenges in the implementation of cardio-oncology trials: lessons learnt from investigating statins in the prevention of anthracycline cardiotoxicity. Cardio-Oncology. 2024;10(1):88. DOI: 10.1186/s40959-024-00292-4

40. Jiang R, Lou L, Shi W, Chen Y, Fu Z, Liu S et al. Statins in Mitigating Anticancer Treatment-Related Cardiovascular Disease. International Journal of Molecular Sciences. 2024;25(18):10177. DOI: 10.3390/ijms251810177

41. Arendt N, Kopsida M, Lennernäs H, Sjöblom M, Heindryckx F. Statin-mediated protection in chemotherapy-induced intestinal and cardiac toxicity: current perspectives. European Journal of Pharmacology. 2025;1007:178282. DOI: 10.1016/j.ejphar.2025.178282

42. TamehriZadeh SS, Khalaji M, Tajdari M, Mavaddat H, Szmit S, Lashgari N-A et al. Statins: Novel Approaches for the Management of Doxorubicin-Induced Cardiotoxicity – A Literature Review. Cardiovascular Toxicology. 2025;25(9):1429–52. DOI: 10.1007/s12012-025-10030-6

43. Juhasz V, Drobni ZD, Quinaglia T, Gilman HK, Suero-Abreu GA, Ghamari A et al. Atorvastatin and left atrial function during anthracycline-based chemotherapy. Journal of Cardiovascular Magnetic Resonance. 2025;27(2):101946. DOI: 10.1016/j.jocmr.2025.101946

44. Chou E, Legasto CS, Chin AK, Baik AH, Schulte BC. Statin Use in Patients With Cancer: drug interaction and statin usage. JACC: Advances. 2025;4(11):102259. DOI: 10.1016/j.jacadv.2025.102259

45. Liao Y, Lin Y, Ye X, Shen J. Concomitant Statin Use and Survival in Patients With Cancer on Immune Checkpoint Inhibitors: A Meta-Analysis. JCO Oncology Practice. 2025;21(7):989–1000. DOI: 10.1200/OP-24-00583

46. Yang J, Lin J, Guo H, Wu W, Wang J, Mao J et al. Administration of statins is correlated with favourable prognosis in lung cancer patients receiving immune checkpoint inhibitors. Frontiers in Immunology. 2025;16:1638677. DOI: 10.3389/fimmu.2025.1638677

47. Dalbeni A, Cattazzo F, Vicardi M, Franceschini E, Campani C, Cabibbo G et al. Statins and clinical outcomes in patients with advanced hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab. Scientific Reports. 2025;15(1):41844. DOI: 10.1038/s41598-025-25752-4

48. Ganatra S, Barac A, Armenian S, Cambareri C, Denlinger CS, Dent SF et al. Diagnosis and Management of Cardiovascular Adverse Effects of Targeted Oncology Therapies: Bruton’s Tyrosine Kinase, Immune Checkpoint, and Vascular Endothelial Growth Factor Inhibitors: 2025 ACC Concise Clinical Guidance: A Report of the American College of Cardiology Solution Set Oversight Committee. JACC. 2025;S0735109725099164. [Epub ahead of print]. DOI: 10.1016/j.jacc.2025.10.018

49. Cheng E, Ivanovic M, Chan A, Xu S, Franquiz M, Lee C et al. Cardiac Troponin Screening and Clinical Outcomes in Patients Receiving Immunotherapy. JACC: CardioOncology. 2025;7(6):708–21. DOI: 10.1016/j.jaccao.2025.06.009

50. Lefler DS, Nassif Haddad EF, Nohria A, Agulnik M, Crane J, Fradley MG. Sarcoma: Cardiovascular and Oncologic Considerations: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology. 2025;S2666087325003473. [Epub ahead of print]. DOI: 10.1016/j.jaccao.2025.09.005

51. Loganath K, Lee KK, Oikonomidou O, Hall P, Mills NL, Joshi S et al. Anthracycline Dose, Myocardial Injury, and Change in Left Ventricular Function in the Cardiac CARE Trial. JACC: CardioOncology. 2025;7(6):725–35. DOI: 10.1016/j.jaccao.2025.06.003

52. Alhuneafat L, Guha A, Blaes A, Konety SH. Cancer and Cardiovascular Disease: Shared Risk Factors, Mechanisms, and Clinical Implications: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology. 2025;7(5):453–69. DOI: 10.1016/j.jaccao.2025.07.001

53. Avagimyan AA, Pogosova N, Fogacci F, Urazova O, Djndoyan Z, Mirzoyan L et al. Pharmacological prevention in cardio-oncology: from bench-to-bedside. Heart Failure Reviews. 2025;31(1):7. DOI: 10.1007/s10741-025-10575-2

54. Galindo RJ, Cheng AYY, Longuet C, Ai M, Coskun T, Malik R et al. Insights into the Mechanism of Action of Tirzepatide: A Narrative Review. Diabetes Therapy. 2025; [Epub ahead of print]. DOI: 10.1007/s13300-025-01804-w

55. Lanting VR, Bosch FTM, Martens ESL, Kamphuisen PW, Barco S, Lecumberri R et al. Management of recurrent venous thromboembolism during anticoagulant treatment in patients with cancer: a prospective cohort study. Journal of Thrombosis and Haemostasis. 2025;23(12):3932–9. DOI: 10.1016/j.jtha.2025.08.022

56. Takano K, Hayashi K, Kitamura K, Kanda M, Ito K, Hirai T et al. SGLT2 Inhibitors Modify Fibrosis-4 Index and Mitigate the Development of DKD: Role of Background Antidiabetic Drugs. Journal of the Endocrine Society. 2025;9(11):bvaf135. DOI: 10.1210/jendso/bvaf135

57. Koo CY, Chong B, Jayabaskaran J, Nagarajan S, Jauhari SM, Chen Y et al. Global Trends and Forecast of Cardiovascular Diseases, Cancer, and Shared Risk Factors: Insights From the GBD 2021. Journal of the American Heart Association. 2025;14(21):e043629. DOI: 10.1161/JAHA.125.043629

58. Szmit S, Kępski J, Lech-Marańda E, Kowalski DM, Krzakowski M, Zaborowska-Szmit M. Anticoagulant therapy in patients with cancer and thrombocytopenia. Journal of Thrombosis and Thrombolysis. 2025; [Epub ahead of print]. DOI: 10.1007/s11239-025-03188-x

59. Seth L, Bhave A, Kollapaneni S, Shah V, Nahle T, Blaes A et al. Cardiotoxic Effects of Antibody Drug Conjugates vs Standard Chemotherapy in ERBB2-Positive Advanced Breast Cancer: A Systematic Review and Meta-Analysis. JAMA Network Open. 2025;8(11):e2540336. DOI: 10.1001/jamanetworkopen.2025.40336

60. Hundal J, Ashruf OS, Li H, Basen-Engquist K, Kaelber DC, Sukumar JS. Racial and demographic disparities in glp-1ra use among breast cancer patients with Type 2 Diabetes. NPJ Breast Cancer. 2025;11(1):131. DOI: 10.1038/s41523-025-00844-6

61. Schmidt ME, Goldschmidt S, Kreutz C, Müller J, Schneeweiss A, May AM et al. Effects of aerobic or resistance exercise during neoadjuvant chemotherapy on tumor response and therapy completion in women with breast cancer: The randomized controlled BENEFIT trial. Journal of Sport and Health Science. 2025;14:101064. DOI: 10.1016/j.jshs.2025.101064

62. Vilsbøll T, Stellfeld M, Aroda VR, Dandanell S, David J, Kristiansen CTP et al. Assessment of thyroid cancer risk associated with glucagon‐like peptide 1 receptor agonist use. Diabetes, Obesity and Metabolism. 2025;70291. [Epub ahead of print]. DOI: 10.1111/dom.70291

63. Andres MS, Llamedo MC, Ramalingam S, Lyon AR. Immunotherapy and the heart: understanding the cardiovascular risks of immune checkpoint inhibitors. La Presse Médicale. 2025;104327. DOI: 10.1016/j.lpm.2025.104327

64. Kelters IR, Printezi MI, Ballesta A, Dierickx P, Koop Y, Innominato PF et al. Chronotherapy as a novel strategy to limit anthracycline-induced cardiotoxicity. Cardiovascular Research. 2025;121(14):2144–56. DOI: 10.1093/cvr/cvaf179

65. Omland T, Heck SL, Holte E, Lilleaasen AM, Gynnild MN, Fagerland MW et al. Sacubitril/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. Circulation. 2025;152(16):1136–45. DOI: 10.1161/CIRCULATIONAHA.125.076616

66. Bonatto MG, Avila MS, Ayub Ferreira SM, Lechinewski LD, Torres R de A, Costa A de N et al. Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial. Circulation. 2025; [Epub ahead of print]. DOI: 10.1161/CIRCULATIONAHA.125.073322

67. Ghigo A, Ameri P, Asnani A, Bertero E, De Boer RA, Farmakis D et al. Update on preclinical models of cancer therapy‐related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio‐Oncology, and the ESC Working Group on Cellular Biology of the Heart. European Journal of Heart Failure. 2025;27(6):1028–46. DOI: 10.1002/ejhf.3636

68. State Register of Medicines. https://grls.minzdrav.gov.ru.